Exploiting the T790M Mutation: Sulfur-Anchoring as a New Paradigm for Non-Covalent EGFR Inhibition

Read full text
Authors: Shrikant S. Nilewar, Shuvadip Khanra, Manav Pandya, Sandesh Lodha, Perli Kranti Kumar, Nagaraju Bandaru, Antonio Jose Naranjo-Redondo, Ricardo Pérez-Pastén-Borja, Tushar Janardan Pawar
Cited by: 1

Abstract

Background/Objectives: The EGFR T790M gatekeeper mutation drives resistance in non-small cell lung cancer by sterically hindering inhibitors and restoring ATP affinity. As emerging C797S mutations render covalent inhibitors obsolete, novel non-covalent strategies are critical. This study identifies inhibitors that redefine the mutant methionine sulfur atom as a primary stabilizing anchor rather than a liability. Methods: A reinforcement learning-based generative AI framework (DrugEx) sampled 100,000 molecules, prioritized through QSAR-based classification (mean ROC-AUC: 0.91 ± 0.01) and physicochemical filtering. Four lead candidates underwent 200 ns all-atom molecular dynamics (MD) simulations. Mechanistic stability and energetic convergence were quantified via Free Energy Landscape (FEL) analysis, post-simulation Ramachandran validation, and ensemble-averaged Molecular Mechanics Generalized Born Surface Area (MM-GBSA) binding free energy calculations. Results: Candidate 106 demonstrated high mutation tolerance by redistributing interactions toward the Met790 sulfur atom, contrasting with reference scaffolds 14 and 88 which suffered significant affinity loss. MD analysis revealed that potency is fundamentally dictated by successful recruitment of the thioether environment, locking the complex within a narrow, well-defined thermodynamic basin. Candidate 106 maintained stable binding (−11.0 kcal/mol by docking) corroborated by a robust MM-GBSA ΔGbind of −50.51 kcal/mol, primarily driven by persistent π-sulfur contacts (85% occupancy). Ramachandran analysis confirmed over 90% favored region occupancy, ensuring interactions occur without non-physical protein strain. Conclusions: Successful T790M/C797S resistance bypass is achievable by exploiting the gatekeeper methionine’s electronic environment. This mutation-aware blueprint provides a non-covalent strategy that avoids the metabolic and resistance-prone liabilities of covalent warheads.

Fields of Study & Subjects

Computational Drug Discovery Methods Lung Cancer Treatments and Mutations Protein Degradation and Inhibitors

Publication details

Journal / source
Preprints.org
Publisher
MDPI AG
Publication date
29 April 2026
Document type
Preprint